Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Single Ascending Dose Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Subjects

Next Previous
Trial Profile

A Phase 1, Open-Label, Single Ascending Dose Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vorasidenib (Primary)
  • Indications Glioma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Agios Pharmaceuticals

Most Recent Events

  • 12 Sep 2023 Results evaluating the Pharmacokinetics of Vorasidenib in Healthy Japanese & Non-Asian Participants presented at the 2023 American College of Clinical Pharmacology Annual Meeting.
  • 01 Apr 2020 Status changed from recruiting to completed.
  • 03 Feb 2020 Planned End Date changed from 18 Dec 2019 to 22 Jun 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top